Ann: Positive in vitro data for CHM 1301 CAR NK cells-supplement, page-8

Thanks for the link.

CHM's AML trial is at MDA Texas and if I recall it correctly the current CHM 1101 ph1b got them as one trial site as well.

And all that plus the other platforms for AUD 5m. The ASX " really got an understanding" of valuing CHM.

The re-rate will come at some stage, fortunately I got the time to wait. One of those rare opportunities to lay a foundation for a huge windfall if the data turn into approved treatments. Not to mention the benefits for cancer sufferers.

GLTA